Glazer W M, Moore D C, Bowers M B, Bunney B S, Roffman M
Psychopharmacology (Berl). 1985;87(4):480-3. doi: 10.1007/BF00432517.
Thirty-one psychiatric outpatients with tardive dyskinesia (TD) on neuroleptic medication were followed in a double-blind, randomized trial comparing baclofen (30-90 mg per day) to placebo. A repeated measures analysis of variance revealed no statistical difference between the baclofen-treated group and the placebo group for the total Abnormal Involuntary Movement Scale (AIMS) scores. There was a trend (P = 0.09) for an initial improvement, then a worsening of frequency counts across four visits. The authors attempt to explain this finding on the basis of information obtained from animal research.
31名正在服用抗精神病药物且患有迟发性运动障碍（TD）的精神科门诊患者参与了一项双盲随机试验，该试验比较了巴氯芬（每天30 - 90毫克）与安慰剂的效果。重复测量方差分析显示，巴氯芬治疗组和安慰剂组在异常不自主运动量表（AIMS）总分上没有统计学差异。在四次就诊过程中，出现了一种趋势（P = 0.09），即最初有改善，随后频率计数恶化。作者试图根据从动物研究中获得的信息来解释这一发现。
